Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANGO 
AngioDynamics Inc (ANGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: ANGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.5
1 Year Target Price $18.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.83% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 508.41M USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Price to earnings Ratio - | 1Y Target Price 18.5 | ||
Volume (30-day avg) 3 | Beta 0.78 | 52 Weeks Range 6.57 - 13.50 | Updated Date 10/27/2025 |
52 Weeks Range 6.57 - 13.50 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-02 | When Before Market | Estimate -0.12 | Actual -0.1 |
Profitability
Profit Margin -10.67% | Operating Margin (TTM) -10.43% |
Management Effectiveness
Return on Assets (TTM) -5.2% | Return on Equity (TTM) -17.1% |
Valuation
Trailing PE - | Forward PE 96.15 | Enterprise Value 443926168 | Price to Sales(TTM) 1.69 |
Enterprise Value 443926168 | Price to Sales(TTM) 1.69 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA 247.75 | Shares Outstanding 41199844 | Shares Floating 32066663 |
Shares Outstanding 41199844 | Shares Floating 32066663 | ||
Percent Insiders 6.44 | Percent Institutions 92.42 |
Upturn AI SWOT
AngioDynamics Inc
Company Overview
History and Background
AngioDynamics, Inc. was founded in 1988. The company develops, manufactures, and sells medical devices used by interventional radiologists, surgeons, and other specialists for vascular access, peripheral vascular disease, and oncology. Over time, it has expanded its product portfolio through internal development and strategic acquisitions.
Core Business Areas
- Vascular Interventions & Therapies: Includes products for thrombus management, venous access, and peripheral vascular interventions.
- Oncology: Focuses on products for ablation and other oncology therapies, including NanoKnife.
- Vascular Access: Products for dialysis access and central venous catheter insertion.
Leadership and Structure
The leadership team typically includes a CEO, CFO, and various Vice Presidents overseeing different business units (e.g., Sales, Marketing, R&D, Operations). The organizational structure is generally functional, with departments aligned by expertise and reporting to senior management.
Top Products and Market Share
Key Offerings
- NanoKnife Ablation System: A non-thermal ablation technology for treating tumors. Market share data is not publicly available in a precise number, but AngioDynamics is a significant player in irreversible electroporation. Competitors include Medtronic (for RF ablation) and Boston Scientific (for microwave ablation).
- AngioVac System: A device for removing thrombus or emboli from the vasculature. The market share information for this product is not publicly available in a precise number. Competitors include Penumbra and Inari Medical.
- Dialysis Catheters: Catheters used for hemodialysis. No reliable individual market share data is available publicly. Competitors include Bard (BDX), Medtronic (MDT), and Teleflex (TFX).
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, regulatory scrutiny, and intense competition. Trends include minimally invasive procedures, personalized medicine, and the increasing use of technology in healthcare. Growing aging population and increasing prevalence of chronic diseases, increasing number of hospital admissions
Positioning
AngioDynamics is a mid-sized player in the medical device industry, focusing on niche markets within vascular and oncology. Its competitive advantages include its innovative technology (e.g., NanoKnife), strong relationships with key opinion leaders, and focused sales and marketing efforts.
Total Addressable Market (TAM)
The total addressable market for the devices AngioDynamics Inc provides depends on the specific area. The overall medical devices market is in the hundreds of billions. AngioDynamics is positioned in certain areas of this TAM with its products. This TAM can be impacted by market regulations and adoption of product.
Upturn SWOT Analysis
Strengths
- Innovative products (e.g., NanoKnife)
- Strong relationships with physicians
- Focused sales and marketing
- Diversified product portfolio
- Established distribution network
Weaknesses
- Smaller size compared to major competitors
- Limited financial resources for large-scale acquisitions
- Dependence on key products
- Price sensitivity.
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary businesses
- Increasing adoption of minimally invasive procedures
- Partnerships with larger medical device companies
Threats
- Intense competition from larger players
- Regulatory changes and approvals
- Pricing pressure from healthcare providers
- Technological obsolescence
- Economic downturn affecting hospital budgets
Competitors and Market Share
Key Competitors
- Boston Scientific (BSX)
- Medtronic (MDT)
- Becton, Dickinson and Company (BDX)
- Teleflex (TFX)
- Penumbra (PEN)
Competitive Landscape
AngioDynamics has a smaller footprint than market leaders. Its competitive advantage is innovation in areas like NanoKnife. It faces challenges in competing on price and scale with larger companies.
Major Acquisitions
BioWave LLC
- Year: 2020
- Acquisition Price (USD millions): 40
- Strategic Rationale: Expanded AngioDynamics' portfolio with a non-opioid pain management therapy, providing an alternative for patients seeking pain relief.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, influenced by product launches, acquisitions, and market conditions.
Future Projections: Future growth depends on factors such as new product development, market expansion, and regulatory approvals. Analyst estimates vary, and financial news sources should be consulted for up-to-date projections.
Recent Initiatives: Recent initiatives often include product development, acquisitions, and strategic partnerships aimed at expanding market share and improving profitability.
Summary
AngioDynamics is a mid-sized medical device company with innovative products, particularly in oncology ablation. It faces stiff competition from larger players, but its focused approach and strong physician relationships are working well. It needs to watch out for regulatory changes and the pace of technological advancement, while also controlling costs and creating growth opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Financial news sources
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data and financial metrics are approximations and may not be exact. Real-time data was not retrievable at the time of the report. It is recommended to consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AngioDynamics Inc
Exchange NASDAQ | Headquaters Latham, NY, United States | ||
IPO Launch date 2004-05-27 | CEO, President & Director Mr. James C. Clemmer | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 675 | Website https://www.angiodynamics.com |
Full time employees 675 | Website https://www.angiodynamics.com | ||
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.